A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer

Sai-Fung Chung1, Chi-Fai Kim1, Suet-Ying Tam1

  • 1Department of Applied Biology and Chemical Technology, Lo Ka Chung Research Centre for Natural Anti-Cancer Drug Development and State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China.

Insights

This study developed a site-specific mono-PEGylated human arginase I mutant for cancer therapy. The enhanced enzyme, enriched with cobalt or nickel, effectively depletes L-arginine and inhibits multiple cancer cell lines.

Area of Science:

  • Biochemistry
  • Biotechnology
  • Oncology

Background:

  • L-arginine (L-Arg) depletion is a promising cancer therapy strategy.
  • Existing arginine-depleting enzymes face challenges like random PEGylation, low efficacy, and immunogenicity.

Purpose of the Study:

  • To develop a homogeneous and highly active PEGylated human arginase I mutant for enhanced cancer therapy.
  • To evaluate the catalytic efficiency, activity, and in vitro/in vivo efficacy of the modified enzyme.

Main Methods:

  • Screening of ten catalytic metal ions for human arginase I mutant (HAI) enrichment.
  • Site-specific mono-PEGylation of HAI at Cys45 using PEG-maleimide.
  • Enzyme kinetics, circular dichroism, in vitro cancer cell growth inhibition assays, and in vivo pharmacodynamic studies in mice.

Main Results:

  • Site-specific mono-PEGylation of HAI was successfully achieved without compromising enzyme activity or structure.
  • Cobalt (Co)- and Nickel (Ni)-enriched HAI exhibited significantly higher catalytic efficiency compared to Manganese (Mn)-enriched HAI.
  • Co- and Ni-HAI-PEG20L demonstrated potent inhibition against eight cancer cell lines and maintained L-Arg depletion for over 120 hours in mice.

Conclusions:

  • Site-specific mono-PEGylated human arginase I mutants enriched with Co or Ni are effective L-arginine depleting agents.
  • These modified enzymes show significant promise as well-tolerated and homogeneous therapeutic candidates for cancer treatment.